iRegene Received Clinical Trial Clearances for Eye Therapy
Regulators in the U.S. and China have approved testing for a new photoreceptor cell therapy treating retinitis pigmentosa.
Updated on Sept. 29, 2026 in Biotech
Live Poll
Do you believe current regulatory processes adequately support the development of new treatments for rare diseases?
iRegene Therapeutics has secured regulatory approval to launch clinical trials for its NouvSight001 therapy in both the United States and China. The treatment, which targets the rare condition retinitis pigmentosa, is developed through a proprietary AI and chemical induction platform.
Why it matters
Clinical trials are essential to determine the safety, tolerability, and efficacy of this new allogeneic photoreceptor cell therapy. These regulatory milestones bring a potential new treatment option closer to the 1.5 million people worldwide currently living with this degenerative eye disease.
NouvSight001 is an allogeneic, off-the-shelf photoreceptor cell therapy created using a proprietary AI and chemical induction platform. The technology functions by identifying biological networks and regulating them through the use of small molecules.
The players
iRegene Therapeutics
This biotechnology company focuses on developing cell therapies through AI-driven chemical induction platforms.
U.S. Food and Drug Administration
This federal agency is responsible for protecting public health by regulating the safety and efficacy of medical products in the United States.
National Medical Products Administration
This is the primary regulatory authority in China responsible for the supervision and approval of drugs and medical devices.
The details
The U.S. Food and Drug Administration granted NouvSight001 a Phase I/II trial clearance and a special exemption for the study. Simultaneously, the National Medical Products Administration in China cleared the therapy for a Phase I/III clinical trial to further investigate its medical utility.
Timeline
In 2024, the FDA granted NouvSight001 Orphan Drug Designation.
On September 29, 2026, iRegene announced the receipt of these international regulatory clearances.
The Tech Race
This trial clearance follows the precedent set by the FDA Orphan Drug Designation to accelerate research for rare diseases. The development underscores a broader industry shift toward utilizing AI-driven chemical platforms to engineer off-the-shelf regenerative medical solutions.
Patients living with retinitis pigmentosa may eventually gain access to a new, off-the-shelf therapy that could address the underlying causes of their vision loss. The trials represent a critical step toward validating this experimental procedure for potential future use in clinical practice.
The takeaway
NouvSight001 represents a significant milestone in using small molecule regulation to repair damaged biological networks in the eye. Researchers and patients should watch for future updates on global multicenter study results as the company explores international partnerships.
Further reading
For more on the latest advancements in genetic and cellular medicine, explore our Biotech coverage.
Live Poll
Do you believe current regulatory processes adequately support the development of new treatments for rare diseases?
